Table 1. . Select randomized trials investigating immune checkpoint blockers in melanoma.

Author	Year	Phase	Setting	n	Treatments	ORR (%)	mOS (months)	Ref.
Anti-CTLA-4 agents
Hodi et al.	2010	III	Pretreated	676	Ipilimumab 3 mg/kg (A) vs ipilimumab 3 mg/kg + gp100 (B) vs gp100 (C)	10.9 (A) vs 5.7 (B) vs 1.5 (C)	10.1 (A) vs 10.0 (B) vs 6.4 (C)	[6]
Robert et al.	2010	III	Treatment-naive	502	Ipilimumab 10 mg/kg + DTIC vs placebo + DTIC	15.2 vs 10.3	11.2 vs 9.1	[7]
Ribas et al.	2013	III	Treatment-naive	655	Tremelimumab vs DTIC or TMZ	10.7 vs 9.8	12.6 vs 10.7	[28]
Anti-PD-1 agents
Robert et al.	2014	I randomized	Pre-treated with anti-CTLA-4	173	Pembrolizumab 2 vs 10 mg/kg	26 vs 26	NR	[29]
Weber et al.	2014	III	Pre-treated with anti-CTLA-4	370	Nivolumab 3 mg/kg vs CT	32 vs 11	NA	[30]
Robert et al.	2015	III	Treatment-naive	418	Nivolumab 3 mg/kg vs DTIC	40 vs 13.9	NR vs 10.8	[8]
Robert et al.	2015	III	Up to one prior systemic treatment	834	Pembrolizumab 10 mg/kg every 2 weeks vs every 3 weeks vs ipilimumab 3 mg/kg	33.7 vs 32.9 vs 11.9	NR	[31]
Anti-PD-1 in combination with anti-CTLA-4
Postow et al.	2015	II randomized	Treatment-naive	142 (109 BRAF wild-type)	Ipilimumab 3 mg/kg + nivolumab 1 mg/kg followed by nivolumab 3 mg/kg vs ipilimumab 3 mg/kg+ placebo	61 vs 11†	NR	[32]

^†Among patients with BRAF wild-type tumors.

CT: Investigator's choice of chemotherapy; DTIC: Dacarbazine; mOS: Median overall survival; NA: Not available or not reported; NR: Not reached; ORR: Overall response rate (complete response + partial response); TMZ: Temozolomide.